Acute myeloid leukemia unlikely related to trabectedin treatment.

摘要

Liu et al. [1] reported a case of acute my-eloid leukemia (AML) in a 24-year-old patient who received trabectedin for advanced Ewing's sarcoma. The patient had been diagnosed with Ewing's sarcoma in 1998 and treated with doxorubicin and if-osfamide in the neoadjuvant setting, and with vincristine, doxorubicin and cyclo-phosphamide alternating with ifosfamide and etoposide, followed by an autologous stem cell transplantation plus interferon for 3 years at first relapse. At the second relapse, 4 years later, trabectedin (1.5 mg/m2 every 4 weeks) was administered for 5 months. Four months after trabectedin discontinuation, the patient developed AML.